HAP PA-HEN Achieving More Together
|
|
- Doris Price
- 5 years ago
- Views:
Transcription
1 HAP PA-HEN Achieving More Together Managing Hyperglycemia in the Hospital: Strategies for Safe and Effective Care Pennsylvania Patient Safety Authority
2 Managing Hyperglycemia in the Hospital: Strategies for Safe and Effective Care Scott R. Drab, PharmD, CDE, BC-ADM Director, University Diabetes Care Associates Associate Professor of Pharmacy & Therapeutics University of Pittsburgh School of Pharmacy Pittsburgh, Pennsylvania 2
3 Learning Objectives Describe the current guidelines for treating hyperglycemia in critically ill and non-critically ill patients Develop strategies to prevent hypoglycemia in the inpatient setting Outline processes and procedures for an appropriate transition from the hospital to outpatient care 3
4 Patients with Unknown Diabetes are a Significant Percentage ICU Admissions 15,737 patients in 9 ICUs Patients with diabetes had significantly more glycemic control challenges than patients without diabetes 5,635 patients diabetes diagnosis in ICU 1,460 (26%) of these had unknown diabetes and were: 41.0% of patients with an hemoglobin A1c > 6.5% 9.3% of all ICU patients. Higher likelihood of requiring an insulin infusion (44.3% vs 29.3%; p<0.0001) Higher average blood glucose (172 vs 126 mg/dl; p<0.0001) More hyperglycemia (19.7% vs 7.0%; blood glucose > 180 mg/dl; p<0.0001) More hypoglycemia (8.9% vs 2.5%; blood glucose < 70 mg/dl; p<0.0001), Higher glycemic variability (55.6 vs 28.8, average of patient SD of glucose; p<0.0001) Compared to patients without diabetes, patients with diabetes had significantly higher risk of mortality (13.8% vs 11.4%; p = 0.01) Carpenter DL, et al. Crit Care Med. 2015;43(12):e
5 Causes of Hospital-related Hyperglycemia Text boxes with % s can be animated Known diabetes (uncontrolled, undertreated) 70-80% of patients with diabetes and critical illnesses, and cardiac surgery have hyperglycemia Undiagnosed diabetes Stress hyperglycemia (transient physiologic response to the stress of acute illness or injury) Iatrogenic (corticosteroids, catecholamines, parenteral and enteral nutrition, reduced exercise) ~33% of patients have significant hyperglycemia without diabetes Corsino L et G, et al., In: De Groot LJ, Beck-Peccoz P, Chrousos G, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; Available at Accessed December 29,
6 Patient-days (%) Glycemic Control in Hospitals* in the United States Hyperglycemia prevalence (>180 mg/dl) Hypoglycemia prevalence (<70 mg/dl) ICU Non-ICU *N=635 A total of 51,375,764 POC-BG measurements (non-icu, 39,197,762; ICU, 12,178,002) from 2,612,966 patients (non-icu, 2,415,209; ICU, 575,084) Bersoux S et al. Endocr Pract. 2015;21(9):
7 Uncontrolled Hyperglycemia is Associated with Poorer Outcomes in Hospitalized Patients in Different Clinical Situations Significant Hyperglycemia-related Outcomes Clinical Situations Mortality risk Total parenteral nutrition 1 Noncardiac surgery 2 Critical care 3 Cardiac surgery 4,5 Aneurysmal subarachnoid hemorrhage 6 Chronic obstructive pulmonary disease 7 Surgery-specific risk, surgical complications Noncardiac surgery 2 Critical care 3 Infections Total parenteral nutrition 1 Cardiac surgery 4,5 Critically injured trauma patients 8 Length of stay Critically injured trauma patients 7 Chronic obstructive pulmonary disease 8 Community-acquired pneumonia 9 Impaired prognosis/adverse outcomes (e.g., complications, renal failure, ventilator time, etc.) Total parenteral nutrition 1 Aneurysmal subarachnoid hemorrhage 6 Chronic obstructive pulmonary disease 8 Community-acquired pneumonia 1. Pasquel FJ et al. Diabetes Care. 2010;33(4): Frisch A et al. Diabetes Care. 2010;33(8): Falciglia M et al. Crit Care Med. 2009;37(12): Furnary AP et al. J Thorac Cardiovasc Surg. 2003;125(5): Furnary AP et al. Ann Thorac Surg. 199;67(2) Schlenk F et al. Neurocrit Care. 2009;11(1): Baker EH et al. Thorax. 2006;61(4): Bochicchio GV et al. J Trauma. 2007;63(6): McAllister FA et al. Diabetes Care. 2005;28(4):
8 Diagnosis and Recognition of Hyperglycemia and Diabetes in the Hospital Setting Admission Assess all patients for a history of diabetes Obtain laboratory BG testing on admission No history of diabetes BG <140 mg/dl No history of diabetes but BG >140 mg/dl History of diabetes Initiate POC BG monitoring according to clinical status Start POC BG monitoring x hours Check A1C level BG monitoring A1C level 6.5% POC BG = point-of-care blood glucose testing. Umpierrez GE et al; Endocrine Society. J Clin Endocrinol Metab. 2012;97(1):
9 Current Recommendations for Hospitalized Patients All critically ill patients in intensive care unit settings BG level mg/dl Pre-meal: < 140 mg/dl Intravenous insulin preferred Non critically ill patients Random: < 180 mg/dl Scheduled SC insulin preferred Sliding-scale insulin discouraged Hypoglycemia Reassess the regimen if BG level is < 100 mg/dl Modify the regimen if BG level is < 70 mg/dl AACE and ADA Consensus Statement on Inpatient Statement on Inpatient Glycemic Control. Endocr Pract. 2009;15: Management of Hyperglycemia in Hospitalized Patients in Non-Critical Care Setting: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab, 2012;97:
10 Insulin is the Preferred Treatment for Hyperglycemia in the Hospital Setting Critically ill patients in the ICU Use IV insulin infusion to treat persistent hyperglycemia Non-critically ill patients Scheduled subcutaneous insulin therapy with basal, nutritional, and correctional components ICU=intensive care unit; IV=intravenous Handelsman Y, et al. Endocrine Practice. 2015;21(suppl 1):1-87.; Moghissi ES et al; American Association of Clinical Endocrinologists; American Diabetes Association. Endocr Pract. 2009;15(4): American Diabetes Association. Diabetes Care. 2009;32(suppl 10 1):S1 S110.
11 Why Insulin is the Most Appropriate Agent for Critically Ill Hospitalized Patients Most potent glucose-lowering agent Critically Ill Patients IV Insulin Rapidly effective Easily titratable (up or down) No significant contraindications Moghissi ES et al; American Association of Clinical Endocrinologists; American Diabetes Association. Endocr Pract. 2009;15(4): American Diabetes Association. Diabetes Care. 2009;32(suppl 1):S1 S
12 Successful IV Insulin Protocol Reaches and maintains BG successfully within a prespecified target range Includes a clear algorithm for making temporary corrective changes in the IV insulin rate as patient requirements change Incorporates the rate of change in BG, not just the absolute values Incorporates the current IV insulin rate Minimizes hypoglycemia; provides specific directions for its treatment when it occurs Provides specific guidelines for timing and selection of doses for the transition to SC insulin Does your institution have an IV insulin protocol in place? Clement S et al. Diabetes Care. 2004;27(2):
13 Safe Use of IV Insulin Therapy Insulin infusion concentrations and protocols should be standardized within a hospital. All MDs/RNs should be trained with competence and assessed regularly. Accurate bedside BG monitoring done hourly (and if stable, every 2 hours). Potassium should be monitored and given if necessary. Clement S et al. Diabetes Care. 2004;27(2):
14 Pharmacological Treatment of Hyperglycemia in Non- ICU Setting Antihyperglycemic Therapy SC Insulin Recommended for most medical-surgical patients OADs Not Generally Recommended Continuous IV Infusion Selected medical-surgical patients ACE/ADA Task Force on Inpatient Diabetes. Diabetes Care & 2009 Umpierrez et al, Endocrine Society Non-ICU Guideline. J Clin Endocrinol Metabol. 97: January 2012 Smiley et al. HospMed. 2010;5:
15 Plasma Insulin ( U/mL) Basal-bolus Therapy Is Effective for the Maintenance of Glycemic Control Effective insulin therapy may contain basal, bolus, and supplemental doses to achieve target goals Breakfast Lunch Dinner Bolus (nutritional) insulin Basal insulin Correction insulin Basal-bolus is more effective at glycemic control vs SSI therapy in medical and surgical patients. 3, :00 12:00 16:00 20:00 24:00 4:00 8:00 Time Adapted from Bray et al Moghissi ES et al; American Association of Clinical Endocrinologists; American Diabetes Association. Endocr Pract. 2009;15(4): Bray B. Consult Pharm. 2008;23(suppl B): Roberts G et al. Med J Aust. 2012;196(4): Umpierrez GE et al. Diabetes Care. 2011;34(2):
16 SC Insulin Administration Scheduled (SSI only uses this component) Correction Basal Bolus (Nutritional) Correction Total daily insulin needs Basal Nutritional Long-acting insulin Rapid-acting insulin Moghissi ES et al; American Association of Clinical Endocrinologists; American Diabetes Association. Endocr Pract. 2009;15(4): Clement S et al. Diabetes Care. 2004;27:
17 SC Correction Insulin Algorithms Does NOT replace scheduled insulin Rather, it corrects for changing needs Based on the insulin sensitivity of the patient Inferred from total daily insulin requirement, or Inferred from weight/bmi Utilize same rapid-acting analog as that of the nutritional (bolus) insulin Need rapid onset and short duration of action Umpierrez GE et al; Endocrine Society. J Clin Endocrinol Metab. 2012;97(1):
18 Supplemental Insulin Scale BG (mg/dl) Insulin-sensitive Usual Insulin-resistant > > The numbers in each column indicate the number of units of regular or rapid-acting insulin analogs per dose. Supplemental dose is to be added to the scheduled insulin dose. Give half of supplemental insulin dose at bedtime. If a patient is able and expected to eat all or most of his/her meals, supplemental insulin will be administered before each meal following the usual column dose Start at insulin-sensitive column in patients who are not eating, elderly patients, and those with impaired renal function Start at insulin-resistant column in patients receiving corticosteroids and those treated with more than 80 U/day before admission Custom scales can be created, however, they are not the norm Umpierrez GE et al; Endocrine Society. J Clin Endocrinol Metab. 2012;97(1):
19 Why Not Sliding Scale Insulin? Definition Use of a mealtime insulin, typically regular insulin, as the sole insulin for managing a patient s diabetes Potential problems Poor control of hyperglycemia (does not address basal insulin needs) Insulin stacking Hypoglycemia Not preferred method of SC insulin delivery American Diabetes Association. Diabetes Care. 2014;37(suppl 1):S14 S80. Browning LA, Dumo P. Am J Health Syst Pharm. 2004;61(15): Hirsch IB. JAMA. 2009;301(2):
20 Blood Glucose (mg/dl) Blood Glucose (mg/dl) Glucose Levels During Basal-bolus and SSI Treatment Changes in BG concentration after the first day of treatment with basal-bolus with glargine once daily plus glulisine before meals ( ) and with SSI 4 times daily ( ). *P <0.001, P = 0.02, P = A * * B 120 Randomization Duration of Treatment (days) Glucose levels before meals and bedtime. Premeal and bedtime glucose levels were higher throughout the day in the SSI group ( ) compared with basal-bolus regimen ( ) * * * * 120 Breakfast Lunch Dinner Bedtime Duration of Treatment (days) Umpierrez G E et al. Diabetes Care. 2011;34(2): Diabetes care by AMERICAN DIABETES ASSOCIATION Reproduced with permission of AMERICAN DIABETES ASSOCIATION. in the format Republish in continuing education materials via Copyright Clearance Center. 20
21 RABBIT-2 Surgery: Composite Hospital Complications and Outcomes: SSI vs Basal-bolus Insulin Sliding Scale Insulin 20 Basal Bolus Insulin ICU length of stay 3.19 vs 1.23 days; P = SSI vs BB Number of patients with complications* 3 Wound infections** 3 0 Pneumonia 5 1 Acute respiratory failure 4 Acute renal failure Bacteremia Mortality Postsurgery ICU admission *P = 0.003; **P = Umpierrez G E et al. Diabetes Care. 2011;34(2):
22 Benefits of Insulin Analogs vs Human Insulin Insulin analogs are derivatives of human insulin that have undergone one or more chemical modifications to alter the time-action profile of the insulin Time-action profile of SC human insulin does not always match physiologic demand Insulin analogs were designed to more closely mimic normal physiologic insulin secretion patterns 22
23 Insulin Analogs Approved in the US Rapid Acting Insulin lispro (U-100, U- 200) Insulin aspart Insulin glulisine Long Acting Insulin detemir Insulin degludec (U-100, U-200) Insulin glargine (U-100, U- 300) 23
24 Serum Insulin Level Basal Analogs Offer Advantages Theoretical insulin profile 1 Basal analog NPH Compared with NPH, basal insulin analogs provide 2 : Reduced rate of hypoglycemia Once-daily dosing in T2DM Similar reduction in FPG 0 24 Time (hours) FPG = fasting plasma glucose; NPH = neutral protamine Hagedorn. 1. Brunton S et al. J Fam Pract. 2005;54(5): Tanwani LK. Am J Geriatr Pharmacother. 2011;9(11):
25 Relative Insulin Effects Advantages of Rapid-acting Insulin Analogs Theoretical insulin profile 1 * Rapid-acting insulin analogs Regular Human Insulin (RHl) Compared with RHI, rapid-acting insulin analogs 2,3 : Provide a more physiologic response Have a more rapid onset and shorter duration of action Are associated with less severe episodes of hypoglycemia Time (hours) * Theoretical representations of insulin levels over time. Adapted from Freeman JS Freeman JS. J Am Osteopath Assoc. 2009;109(1): Tanwani LK. Am J Geriatr Pharmacother. 2011;9(11): Handelsman Y et al; AACE Task Force for Developing Diabetes Comprehensive Care Plan. Endocr Pract. 2011;17(suppl 2):
26 Avoiding Hypoglycemia 26
27 Essential Part of Any Insulin Use: A Hypoglycemia Protocol Clear definition of hypoglycemia Glucose level (ADA) <70 mg/dl Nursing order to treat without delay Stop insulin infusion (if patient is on one) Oral glucose (if patient is able to take POs) IV dextrose or glucagon (if patient is unable to take POs) Repeat BG monitoring 15 minutes after treatment for hypoglycemia and repeat treatment if BG not up to target Directions for when and how to restart insulin Look for the cause of hypoglycemia and determine if changes in the antihyperglycemic treatment strategy are needed ACE/ADA Task Force on Inpatient Diabetes. Endocr Pract. 2006;12(4): American Diabetes Association. Diabetes Care. 2009;31(suppl 1):S1 S110. Umpierrez GE et al; Endocrine Society. J Clin Endocrinol Metab. 2012;97(1):
28 Hypoglycemia Orders Nurse treat per protocol, treat if bedside BG level <70 mg/dl; notify resident Juice, intravenously administered dextrose, or intramuscularly administered glucagon depending on ability to take oral nutrition and intravenous access Recheck bedside BG level in 15 minutes and repeat as necessary Adapted from Schnipper JL et al. Endocr Pract. 2010;16(2):
29 Transitions of Care 29
30 Transition to Outpatient Status Begin discharge planning early Stabilize blood glucose prior to discharge Obtain A1C for discharge planning if the result is not available from the previous 2 to 3 months A1C can now be used as a means to make the diagnosis of diabetes Moghissi ES, et al. Endocr Pract. 2009;15:
31 Transition to Outpatient Status Provide instruction Medication use / Injection technique if using insulin Basics on diet plan Glucose monitoring Hypoglycemia prevention and treatment Refer patient to a certified diabetes educator Clarify insurance reimbursement to ensure availability of medications at discharge Schedule a follow-up visit with clinician and provide emergency number to call if problems Moghissi ES, et al. Endocr Pract. 2009;15:
32 Questions 32
33 33
4/10/2015. Foundations to Managing Inpatient Hyperglycemia. Learning Objectives
Foundations to Managing Inpatient Hyperglycemia Module A 1 Learning Objectives Develop strategies to identify patients with hyperglycemia or diabetes in the inpatient setting Establish glycemic goals to
More informationTransition of Care in Hospitalized Patients with Hyperglycemia and Diabetes
Transition of Care in Hospitalized Patients with Hyperglycemia and Diabetes Critically ill patients in the ICU Hospital Non-ICU Settings Home Guillermo E Umpierrez, MD, FACP, FACE Professor of Medicine
More informationInpatient Management of Hyperglycemia Guillermo Umpierrez, MD, CDE Saturday, February 10, :30 a.m. 11:15 a.m.
Inpatient Management of Hyperglycemia Guillermo Umpierrez, MD, CDE Saturday, February 1, 218 1:3 a.m. 11:15 a.m. There are over 7.5 million hospital admissions for patients with diabetes in the US. About
More informationInpatient Management of Hyperglycemia Guillermo Umpierrez, MD, CDE Saturday, February 10, :30 a.m. 11:15 a.m.
Inpatient Management of Hyperglycemia Guillermo Umpierrez, MD, CDE Saturday, February 10, 2018 10:30 a.m. 11:15 a.m. There are over 7.5 million hospital admissions for patients with diabetes in the US.
More informationOptimizing Care of the Inpatient with Hyperglycemia and Diabetes: Case Studies in Action
Optimizing Care of the Inpatient with Hyperglycemia and Diabetes: Case Studies in Action Learning Objectives Identify patient situations where specific attention to glycemic control is warranted Determine
More informationANNUAL MEETING 2 #FSHP2017
FSHP Disclosure Strategies for Glycemic Management in the Inpatient Setting: Guidelines vs. Reality Melissa Marshall, PharmD, BCPS Jeffrey Ruff, PharmD We do not have (nor does any immediate family member
More informationEvidence for Basal Bolus Insulin Versus Slide Scale Insulin
Curr Emerg Hosp Med Rep (2014) 2:26 34 DOI 10.1007/s40138-013-0032-4 DIABETES AND METABOLIC DISEASE (W FORD, SECTION EDITOR) Evidence for Basal Bolus Insulin Versus Slide Scale Insulin Sameer Badlani William
More informationMeeting the Challenge of Inpatient Glycemic Management in the Non-Critical Care Setting
Meeting the Challenge of Inpatient Glycemic Management in the Non-Critical Care Setting Jane Jeffrie Seley, DNP, MPH, GNP, BC-ADM, CDE, CDTC, FAAN, FAADE Diabetes Nurse Practitioner, Inpatient Diabetes
More informationInpatient Diabetes Management: The Slippery Slope of Sliding Scale Insulin
Inpatient Diabetes Management: The Slippery Slope of Sliding Scale Insulin David Newman, MD University of North Dakota School of Medicine Sanford Health Big Sky Conference 2017 Dr. David Newman, Personal/Professional
More informationBasal Bolus Insulin Therapy Frequently Asked Questions
1. What is Basal Bolus Insulin Therapy (BBIT)? 2. What evidence supports the use of subcutaneous Basal Bolus Insulin Therapy? 3. Does Basal Bolus Insulin Therapy apply to all patients? 4. What s wrong
More informationΑναγκαιότητα και τρόπος ρύθμισης του διαβήτη στους νοσηλευόμενους ασθενείς
Αναγκαιότητα και τρόπος ρύθμισης του διαβήτη στους νοσηλευόμενους ασθενείς Αναστασία Θανοπούλου Επίκουρη Καθηγήτρια Β Παθολογικής Κλινικής Πανεπιστημίου Αθηνών Διαβητολογικό Κέντρο, Ιπποκράτειο Νοσοκομείο
More informationHow to manage type 2 diabetes in medical and surgical patients in the hospital
MEDICAL GRAND ROUNDS CME CREDIT EDUCATIONAL OBJECTIVE: Readers will learn the relationship between glycemic control and clinical outcomes in hospitalized medical and surgical patients who are not in an
More information123 Are You Providing Evidence-Based Diabetes Care? - Martin
Donna Martin, DNP, RN, CDE, CMSRN Lewis University Learner will be able to: Identify current inpatient standards of care for patients with diabetes Describe causes of hyperglycemia / hypoglycemia in the
More informationDeepika Reddy MD Department of Endocrinology
Deepika Reddy MD Department of Endocrinology Management of hyperglycemic crisis Review need for inpatient glycemic control Brief overview of relevant trials Case based review of diabetes management strategies/review
More informationInpatient Management of Diabetes Mellitus. Jessica Garza, Pharm.D. PGY-1 Pharmacotherapy Resident TTUHSC School of Pharmacy
Inpatient Management of Diabetes Mellitus Jessica Garza, Pharm.D. PGY-1 Pharmacotherapy Resident TTUHSC School of Pharmacy 2 Disclosure Jessica Garza does not have any actual or potential conflicts of
More informationGlycemic Control Insulin In The Hospital Setting
Glycemic Control Insulin In The Hospital Setting Glycemic Control The Evidence For Insulin s s Benefit The Mechanism of Insulin s s Benefit The Achievement of Insulin s s Benefit A Few Cases Hyperglycemia
More informationIn - Hospital Diabetes Care. A review and personal experience
In - Hospital Diabetes Care A review and personal experience Hyperglycemia in the Hospital The Problem Hospitalizations with Diabetes http://www.cdc.gov/diabetes/statistics/dmany/fig1.htm Prevalence of
More informationSection of Endocrinology, Rush University Medical Center, Chicago, Illinois.
ORIGINAL RESEARCH Treatment of Inpatient Hyperglycemia Beginning in the Emergency Department: A Randomized Trial Using Insulins Aspart and Detemir Compared With Usual Care Jennifer B. Bernard, MD Christina
More informationA Children s Bedtime Story
A Children s Bedtime Story Setting: University Medical Center, Big Town, USA Scenario: 0500, last admission of the night, 10 previous admissions, all tucked in for the night Patient: 75 year old male with
More informationNOT-SO-SWEET! THE STRAIGHT SCOOP ON DIABETES IN THE HOSPITAL SETTING
Sharp HealthCare s 2016 Diabetes Conference November 11, 2016 NOT-SO-SWEET! THE STRAIGHT SCOOP ON DIABETES IN THE HOSPITAL SETTING Tamara Swigert, MSN, RN, CDE Speaker Disclosure Tammy Swigert has no conflicts
More informationManaging Diabetes and Hyperglycemia Safely in the Complex Hospital Setting
Managing Diabetes and Hyperglycemia Safely in the Complex Hospital Setting Greg Maynard MD, MSc Clinical Professor of Medicine and CQO, UC Davis Medical Center Sacramento, CA Greg Maynard Disclosure SHM
More informationManagement of Inpatient Hyperglycemia: 2011 Endocrine Society Meeting Hyperglycemia in Critically ill patients in ICU Settings.
Management of Inpatient Hyperglycemia: 2011 Endocrine Society Meeting Guillermo E. Umpierrez, MD, Emory University School of Medicine and Jack Leahy, MD, University of Connecticut Hyperglycemia in Critically
More informationAgenda. Indications Different insulin preparations Insulin initiation Insulin intensification
Insulin Therapy F. Hosseinpanah Obesity Research Center Research Institute for Endocrine sciences Shahid Beheshti University of Medical Sciences November 11, 2017 Agenda Indications Different insulin preparations
More information9/23/09. What are the key components of preoperative, intraoperative, & postoperative care of diabetes management? Rebecca L. Sturges, M.D.
RMHS Perioperative Summit: Perioperative Diabetes Management Rebecca L. Sturges, M.D. Oct 6, 2009 Mrs. B was referred by her orthopedic surgeon to your preoperative clinic to discuss medical management
More informationManagement of Hyperglycemia in Hospitalized Patients in Non-Critical Care Setting:
T h e E n d o c r i n e S o c i e t y s Clinical Guidelines Management of Hyperglycemia in Hospitalized Patients in Non-Critical Care Setting: An Endocrine Society Clinical Practice Guideline Authors:
More information5/15/2018 DISCLOSURE OBJECTIVES. FLORIDA HOSPITAL ORLANDO Not for profit organization Acute care medical center 1,368 licensed beds BACKGROUND
DISCLOSURE PHARMACIST DIRECTED MANAGEMENT OF GLUCOCORTICOID INDUCED HYPERGLYCEMIA AT A LARGE COMMUNITY HOSPITAL Jill Zaccardelli, PharmD PGY1 Pharmacy Resident Florida Hospital Orlando Jill.Zaccardelli@flhosp.org
More informationDisclosures. Glycemic Control in the Intensive Care Unit. Objectives. Hyperglycemia. Hyperglycemia. History. No disclosures
Disclosures Glycemic Control in the Intensive Care Unit No disclosures Jorie Frasiolas, Pharm.D., BCPS Clinical Pharmacy Manager, CTICU NewYork-Presbyterian Hospital Columbia University Medical Center
More informationInpatient Glycemic Management:
Disclosure to Participants Conflict of Interest (COI) and Financial Relationship Disclosures: Dr. Seley attended Advisory Board Meeting: Alliance (Boehringer-Ingelheim/Lilly) Bayer Diabetes Care Sanofi
More informationTimely!Insulinization In!Type!2! Diabetes,!When!and!How
Timely!Insulinization In!Type!2! Diabetes,!When!and!How, FACP, FACE, CDE Professor of Internal Medicine UT Southwestern Medical Center Dallas, Texas Current Control and Targets 1 Treatment Guidelines for
More informationGlucose Management in the ICU: The Role of the Pharmacist
Objectives Glucose Management in the ICU: The Role of the Pharmacist James Gilmore PharmD, BCPS Senior Pharmacist- Surgical Intensive Care Unit Brigham and Women s Hospital Boston, MA Evaluate primary
More informationINSULIN IN THE OBESE PATIENT JACQUELINE THOMPSON RN, MAS, CDE SYSTEM DIRECTOR, DIABETES SERVICE LINE SHARP HEALTHCARE
INSULIN IN THE OBESE PATIENT JACQUELINE THOMPSON RN, MAS, CDE SYSTEM DIRECTOR, DIABETES SERVICE LINE SHARP HEALTHCARE OBJECTIVES DESCRIBE INSULIN, INCLUDING WHERE IT COMES FROM AND WHAT IT DOES STATE THAT
More informationReviewing Diabetes Guidelines. Newsletter compiled by Danny Jaek, Pharm.D. Candidate
Reviewing Diabetes Guidelines Newsletter compiled by Danny Jaek, Pharm.D. Candidate AL AS KA N AT IV E DI AB ET ES TE A M Volume 6, Issue 1 Spring 2011 Dia bet es Dis pat ch There are nearly 24 million
More informationMartin J Stevens MD, FRCP, Endocrinologist and Professor of Medicine
The Approach to Inpatient Hyperglycemia Martin J Stevens MD, FRCP, Endocrinologist and Professor of Medicine Great Lakes Hospital Medical Symposium May 7th 2010 Further Increases in the Prevalence of Diabetes
More informationAPPENDIX American Diabetes Association. Published online at
APPENDIX 1 INPATIENT MANAGEMENT OF TYPE 2 DIABETES No algorithm applies to all patients with diabetes. These guidelines apply to patients with type 2 diabetes who are not on glucocorticoids, have no
More informationHot Topics: The Future of Diabetes Management Cutting Edge Medication and Technology-Based Care
Hot Topics: The Future of Diabetes Management Cutting Edge Medication and Technology-Based Care Mary Jean Christian, MA, MBA, RD, CDE Diabetes Program Coordinator UC Irvine Health Hot Topics: Diabetes
More informationLIBERTYHEALTH. Jersey City Medical Center Department of Patient Care Services. Approved by Policy Committee:
LIBERTYHEALTH Jersey City Medical Center Department of Patient Care Services Guidelines: CRITICAL CARE INSULIN PROTOCOL (MICU/SICU, CCU, ED) Developed by: Pharmacy Dept Approved by: Rita Smith, DNP Senior
More informationWhat s so sweet about glycemic control? June 3, 2016
What s so sweet about glycemic control? June 3, 2016 Objectives Provide an overview of why glucose control is important in surgical patient outcomes. Demonstrate an understanding of how anesthetics and
More informationRecent Advances in the Management of Diabetes
Recent Advances in the Management of Diabetes Raja Hanania, R.Ph,CDM,CDE,LDE,BCPS Clinical Pharmacy Specialist IU Health Bloomington Hospital Bloomington, Indiana Indiana Pharmacists Alliance Annual Convention
More informationDisclosure 1/16/2017. Michael R. Brennan D.O., M.S., F.A.C.E Director Beaumont Endocrine Center Chief of Endocrine Beaumont Grosse Pointe 1/16/2017 2
Therapy For Diabetes Michigan Association of Osteopathic Family Physicians Mid-Winter Family Medicine Update Shanty Creek Resort, MI January 19-22nd 2017 Michael R. Brennan D.O., M.S., F.A.C.E Director
More informationUKPDS: Over Time, Need for Exogenous Insulin Increases
UKPDS: Over Time, Need for Exogenous Insulin Increases Patients Requiring Additional Insulin (%) 60 40 20 Oral agents By 6 Chlorpropamide years, Glyburide more than 50% of UKPDS patients required insulin
More informationPerioperative Management of the Patient with Endocrine Disease: A Focus on Diabetes & Thyroid Dysfunction
Perioperative Management of the Patient with Endocrine Disease: A Focus on Diabetes & Thyroid Dysfunction Luigi Meneghini, MD, MBA Professor, Internal Medicine (Endocrinology), UT Southwestern Medical
More informationUpdate on Insulin-based Agents for T2D. Harry Jiménez MD, FACE
Update on Insulin-based Agents for T2D Harry Jiménez MD, FACE Harry Jiménez MD, FACE Has received honorarium as Speaker and/or Consultant for the following pharmaceutical companies: Eli Lilly Merck Boehringer
More informationGetting Off the Merry-Go-Round Reducing Readmissions for Patients with Diabetes
Getting Off the Merry-Go-Round Reducing Readmissions for Patients with Diabetes Kristi Kulasa, MD Associate Clinical Professor of Medicine Director, Inpatient Glycemic Control University of California
More information5/16/2018. Insulin Update: New and Emerging Insulins. Disclosures to Participants. Learning Objectives
Insulin Update: New and Emerging Insulins Joshua J. Neumiller, PharmD, CDE, FASCP Vice Chair & Associate Professor, Department of Pharmacotherapy Washington State University Spokane, WA Disclosures to
More information9/16/2013. No Conflict of Interest to Disclose
Catie Prinzing MSN, APRN, Clinical Nurse Specialist September 27, 2013 No Conflict of Interest to Disclose List key concepts to determining patient insulin doses during transitions in care Identify 5 points
More informationInpatient Glycemic Management 2016
2016 Jim Chamberlain MD Medical Director for Diabetes Services St. Mark s Hospital and St. Mark s Diabetes Center Salt Lake City, Utah Disclosures Speakers Bureaus Merck & Co. Janssen Pharmaceutical Companies
More informationDisclosure. Disclosure. Disclosure. Course Outline. Objectives. A Touch of Sugar : Controlling Hyperglycemia in Acute Care Settings 7/25/2013
47 th Annual Meeting August 2-4, 2013 Orlando, FL A Touch of Sugar : Controlling Hyperglycemia in Acute Care Settings Kevin Forbush, Pharm. D Central Maine Medical Center Lewiston, Maine Disclosure I do
More informationUpdate on Insulin-based Agents for T2D
Update on Insulin-based Agents for T2D Injectable Therapies for Type 2 Diabetes Mellitus (T2DM) and Obesity This presentation will: Describe established and newly available insulin therapies for treatment
More informationThese Aren t Your Average Rookies: A Primer on New and Emerging Insulins. Alissa R. Segal, Pharm.D, CDE, CDTC, FCCP
These Aren t Your Average Rookies: A Primer on New and Emerging Insulins Alissa R. Segal, Pharm.D, CDE, CDTC, FCCP Disclosures Eli Lilly & Company: Advisory board member Boehringer Ingelheim: Advisory
More informationInsulin therapy in gestational diabetes mellitus
Insulin therapy in gestational diabetes mellitus October 15, 2015 Kyung-Soo Kim Division of Endocrinology & Metabolism, Department of Internal Medicine, CHA Bundang Medical Center, CHA University Contents
More informationWelcome Everyone. Monitoring, Sick Days, Inpatient Management - Objectives. Mrs. Jones has new diabetes. She asks you: Page 1
Welcome Everyone Sign-In Enjoy Breakfast Meet someone new Enter Raffle Pick a team name Please silence phones We start at 8:00am Monitoring, Sick Days, Inpatient Management - Objectives Objectives: Strategies
More informationClinicalTrials.gov Identifier: sanofi-aventis. Sponsor/company:
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinicalTrials.gov
More informationBeyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM
Beyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM Disclosures Jennifer D Souza has no conflicts of interest to disclose. 2 When Basal Insulin Is Not Enough Learning
More informationPeripartum and Postpartum Management of Diabetes
Peripartum and Postpartum Management of Diabetes General Principles Glucose goal ~ 100 mg/dl (70-110 mg/dl) Labor is EXERCISE with increased metabolic demands. Insulin requirements decrease however the
More informationStroke Hyperglycemia Insulin Network Effort (SHINE) Trial Treatment Protocols. Askiel Bruno, MD, MS Protocol PI
Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial Treatment Protocols Askiel Bruno, MD, MS Protocol PI SHINE Synopsis Acute ischemic stroke
More informationInpatient and perioperative management of hyperglycemia
Inpatient and perioperative management of hyperglycemia Department of Internal Medicine Grand Rounds July 7, 2017 Luigi Meneghini discloses that he has served on advisory boards and as consultant for both
More informationParenteral Nutrition The Sweet and Sour Truth. From: Division of Endocrinology, Diabetes and Bone Disease Icahn School of Medicine at Mount Sinai
ENDOCRINE PRACTICE Rapid Electronic Article in Press Rapid Electronic Articles in Press are preprinted manuscripts that have been reviewed and accepted for publication, but have yet to be edited, typeset
More informationSafety and Efficacy of Continuous Insulin Infusion in Noncritical Care Settings
ORIGINAL RESEARCH Safety and Efficacy of Continuous Insulin Infusion in Noncritical Care Settings Dawn Smiley, MD 1 Mary Rhee, MD 1 Limin Peng, PhD 2 Laurian Roediger, BS 1 Patrick Mulligan, BS 1 Lewis
More informationLearning Objectives. Impact of Diabetes II UPDATES IN TYPE 2 DIABETES. David Doriguzzi, PA-C
UPDATES IN TYPE 2 DIABETES David Doriguzzi, PA-C Learning Objectives Upon completion of this educational activity, the participant should be able to: Overcome barriers and attitudes that limit Clinician/Patient
More informationDRUG ALLERGIES WT: KG
DRUG AND TREATMENT Acute Diabetic Ketoacidosis Condition/Status ***(NOTE)*** For purpose of this DKA Regimen, DKA is considered clear only when the CO2 is GREATER than 18 meq/l and the anion gap is LESS
More informationYour Chart Review Data. Lara Zisblatt, MA Assistant Director Continuing Medical Education Boston University School of Medicine
Your Chart Review Data Lara Zisblatt, MA Assistant Director Continuing Medical Education Boston University School of Medicine Participation 243 registered for the program 98 have completed the Practice
More informationThe Diabetes Guidelines Trek: The Next Generation. Inpatient Diabetes Guidelines. Learning Objectives. Current Inpatient Guidelines
The Diabetes Guidelines Trek: The Next Generation J. Christopher Lynch, PharmD, BCACP Southern Illinois University Edwardsville School of Pharmacy Susan Cornell BS, PharmD, CDE, FAPhA, FAADE Midwestern
More informationApril Dear (Editor):
April 2014 Dear (Editor): Registered Dietitians (RD) play an integral role in patient care in the medical intensive care unit. RD s have increased knowledge in blood glucose control and reducing adverse
More informationPharmacy Plan Guidance
Pharmacy Plan Guidance The pharmacy plan is a tool used during the site readiness process to develop and document the site-specific procedures for study drug ordering, labeling and dispensing for the SHINE
More informationManagement of Diabetes and Hyperglycemia in Hospitalized Patients
of 21 11/3/2016 9:02 AM NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health. De Groot LJ, Chrousos G, Dungan K, et al., editors. Endotext [Internet]. South Dartmouth
More informationDiabetes: Definition Pathophysiology Treatment Goals. By Scott Magee, MD, FACE
Diabetes: Definition Pathophysiology Treatment Goals By Scott Magee, MD, FACE Disclosures No disclosures to report Definition of Diabetes Mellitus Diabetes Mellitus comprises a group of disorders characterized
More informationHow to Manage Steroid Diabetes in the Patient With Cancer David S. Oyer, MD, FACE, Ajul Shah, BS, and Susan Bettenhausen, APRN, CDE
H O W W E D O I T How to Manage Steroid Diabetes in the Patient With Cancer David S. Oyer, MD, FACE, Ajul Shah, BS, and Susan Bettenhausen, APRN, CDE G lucocorticosteroids (steroids) have profound effects
More informationInsulin Order Sets & In-Hospital Management of Diabetes
Insulin Order Sets & In-Hospital Management of Diabetes 416591 Table of Contents Key elements from Diabetes Canada 2018 Clinical Practice Guidelines Introduction........................................................
More informationprolonged hospital stay, infections, and disability after hospital discharge, and death (1 3). Several clinical trials in
Clinical Care/Education/Nutrition/Psychosocial Research O R I G I N A L A R T I C L E Randomized Study Comparing a Basal Bolus With a Basal Plus Correction Insulin Regimen for the Hospital Management of
More informationStarting and Helping People with Type 2 Diabetes on Insulin
Starting and Helping People with Type 2 Diabetes on Insulin Elaine Cooke, BSc(Pharm), RPh, CDE Pharmacist and Certified Diabetes Educator Maple Ridge, BC Objectives After attending this session, participants
More informationINSULIN THERAY دکتر رحیم وکیلی استاد غدد ومتابولیسم کودکان دانشگاه علوم پزشکی مشهد
INSULIN THERAY DIABETES1 IN TYPE دکتر رحیم وکیلی استاد غدد ومتابولیسم کودکان دانشگاه علوم پزشکی مشهد Goals of management Manage symptoms Prevent acute and late complications Improve quality of life Avoid
More informationImproving Glycemic Control and Insulin Ordering Efficiency for Hospitalized Patients With Diabetes Through Carbohydrate Counting
e1 Improving Glycemic Control and Insulin Ordering Efficiency for Hospitalized Patients With Diabetes Through Carbohydrate Counting Kristina K. Pearson, Sarah A. Reiland, John G. O Meara, Julie K. Brown,
More informationFaculty. Concentrated Insulin: Examining the Necessity of Newer Insulins for In-Hospital Diabetes Management. Disclosures. Learning Objectives
Examining the Necessity of Newer Insulins for In-Hospital Diabetes Management Faculty Susan Cornell, PharmD, CDE, FAPhA, FAADE Associate Professor of Pharmacy Practice Associate Director of Experiential
More informationIn-hospital management of diabetes
Dr. Tom Elliott MBBS, FRCPC Medical Director 400-210 W Broadway phone: 604.683.3734 Vancouver, BC fax: 604.628.3821 V5Y 3W2 Canada email: moa@bcdiabetes.ca In-hospital management of diabetes General Management
More informationAkio Ohta, Kaori Arai, Ami Nishine, Yoshiyuki Sada, Hiroyuki Kato, Hisashi Fukuda, Shiko Asai, Yoshio Nagai, Takuyuki Katabami and Yasushi Tanaka
Endocrine Journal 2013, 60 (2), 173-177 Or i g i n a l Comparison of daily glucose excursion by continuous glucose monitoring between type 2 diabetic patients receiving preprandial insulin aspart or postprandial
More informationThursday School 2010 Management of Inpatient Diabetes and Hyperglycemia and Quality Improvement Efforts
Thursday School 2010 Management of Inpatient Diabetes and Hyperglycemia and Quality Improvement Efforts Kendall Rogers, MD Using subcutaneous insulin to reliably achieve desired glycemic outcomes in non-critically
More informationInsulin Prior Authorization with optional Quantity Limit Program Summary
Insulin Prior Authorization with optional Quantity Limit Program Summary 1-13,16-19, 20 FDA LABELED INDICATIONS Rapid-Acting Insulins Humalog (insulin lispro) NovoLog (insulin aspart) Apidra (insulin glulisine)
More informationImplementing Glucose Control in 2009 and Beyond: Changes in Patterns and Perceptions
Implementing Glucose Control in 2009 and Beyond: Changes in Patterns and Perceptions Charles C. Reed MSN, RN, CNRN Patient Care Coordinator Surgical Trauma ICU University Hospital San Antonio, Texas Relationships
More informationLearning Objectives. Perioperative SWEET Success
Perioperative SWEET Success PERIOPERATIVE SWEET SUCCESS PRESENTED BY: KENDRA MARTIN, RN, BSN, CDE JENNIFER SIMPSON, RN, BC-ADM, MSN, CNS Disclosure to Participants Notice of Requirements For Successful
More informationInsulin Regimens: Hitting Glycemia Targets
Insulin Regimens: Hitting Glycemia Targets Grant Kelley MD March 1 st, 2018 Faculty Disclosure: Financial relationships with commercial interests None Overview Mortality and Morbidity Insulin and Insulin
More informationIn-Hospital Management of Diabetes
In-Hospital Management of Diabetes Clinical order sets guidelines.diabetes.ca diabetes.ca 1-800-BANTING (226-8464) Table of Contents Key elements from the Canadian Diabetes Association 2013 Clinical Practice
More informationFaculty. Disclosures. Prescribing. A Multidisciplinary Approach to Preventing Medication Errors Associated with Insulin Therapy. Learning Objectives
A Multidisciplinary Approach to Preventing Medication Errors Associated with Insulin Therapy Faculty Matthew Grissinger, RPh, FISMP, FASCP Director, Error Reporting Programs Institute for Safe Medication
More informationThe Hospitalized Child with Diabetes/Hyperglycemia: Don t Sugar Coat It
The Hospitalized Child with Diabetes/Hyperglycemia: Don t Sugar Coat It Cassie Brady, MD Assistant Professor of Pediatrics Division of Endocrinology and Diabetes Monroe Carell Junior Children s Hospital
More informationLOW SUGAR: CAUSES, COMPLICATIONS AND MANAGEMENT OF HYPOGLYCEMIA
LOW SUGAR: CAUSES, COMPLICATIONS AND MANAGEMENT OF HYPOGLYCEMIA Anne Leake, PhD, APRN-Rx, BC-ADM ECHO Diabetes Learning Group 3/28/2018 Objectives 1. Identify common preventable causes of hypoglycemia
More informationCurrent Trends in Diagnosis and Management of Gestational Diabetes
Current Trends in Diagnosis and Management of Gestational Diabetes Shreela Mishra, MD Assistant Clinical Professor UCSF Fresno Medical Education Program 2/2/2019 Disclosures No disclosures 2/2/19 Objectives
More informationHYPERGLYCEMIA MANAGEMENT PROTOCOL A BASAL/BOLUS REGIMEN. Kacy Aderhold, MSN, APRN-CNS, CMSRN
HYPERGLYCEMIA MANAGEMENT PROTOCOL A BASAL/BOLUS REGIMEN Kacy Aderhold, MSN, APRN-CNS, CMSRN Hyperglycemia Management Protocol Mimics the body s normal pancreas function, releasing a slow steady amount
More informationSpecial Situations 1
Special Situations 1 Outline Continuous Nutrition Tube feeds TPN Steroids Pumps Perioperative BG Control 2 Patient receiving continuous TF or TPN Continuous nutrition coverage options: Analog q4hr Regular
More informationInitiating Injectable Therapy in Type 2 Diabetes
Initiating Injectable Therapy in Type 2 Diabetes David Doriguzzi, PA C Learning Objectives To understand current Diabetes treatment guidelines To understand how injectable medications fit into current
More informationFor patients uncontrolled on multiple daily injections of insulin. A quick-start guide for your practice ALL-DAY CONTROL WITH
For patients uncontrolled on multiple daily injections of insulin A quick-start guide for your practice Dosing guidance 1,* V-Go: 3 options 1 For initiating V-Go in patients switching from MDI The majority
More informationDEMYSTIFYING INSULIN THERAPY
DEMYSTIFYING INSULIN THERAPY ASHLYN SMITH, PA-C ENDOCRINOLOGY ASSOCIATES SCOTTSDALE, AZ SECRETARY, AMERICAN SOCIETY OF ENDOCRINE PHYSICIAN ASSISTANTS ARIZONA STATE ASSOCIATION OF PHYSICIAN ASSISTANTS SPRING
More informationGlucose Management in Noncritical Hospitalized Patients
Glucose Management in Noncritical Hospitalized Patients October 17, 2015 Archana R. Sadhu, MD., FACE Director of System Diabetes Program Director of Transplant Endocrinology Assistant Professor, Weill
More informationImplementing Hospital Policies & Protocols
Implementing Hospital Policies & Protocols Jane Jeffrie Seley DNP MPH GNP BC-ADM CDE CDTC FAADE FAAN Division of Endocrinology, Diabetes & Metabolism NewYork-Presbyterian Hospital Weill Cornell Medicine
More informationManaging Diabetes and Hyperglycemia Safely in the Complex Hospital Setting
Managing Diabetes and Hyperglycemia Safely in the Complex Hospital Setting Greg Maynard MD, MSc Clinical Professor of Medicine and CQO, UC Davis Medical Center Sacramento, CA Greg Maynard Disclosure SHM
More informationMANAGEMENT OF HYPERGLYCEMIA IN CRITICALLY ILL SURGICAL (NON-CARDIAC) PATIENTS
DISCLAIMER: These guidelines were prepared by the Department of Surgical Education, Orlando Regional Medical Center. They are intended to serve as a general statement regarding appropriate patient care
More informationnocturnal hypoglycemia percentage of Hispanics in the insulin glargine than NPH during forced patients who previously This study excluded
Clinical Trial Design/ Primary Objective Insulin glargine Treat-to-Target Trial, Riddle et al., 2003 (23) AT.LANTUS trial, Davies et al., 2005 (24) INSIGHT trial, Gerstein et al., 2006 (25) multicenter,
More informationNew basal insulins Are they any better? Matthew C. Riddle, MD Professor of Medicine Oregon Health & Science University Keystone Colorado 15 July 2011
New basal insulins Are they any better? Matthew C. Riddle, MD Professor of Medicine Oregon Health & Science University Keystone Colorado 15 July 2011 Presenter Disclosure I have received the following
More informationPHYSICIAN SIGNATURE DATE TIME DRUG ALLERGIES WT: KG
DRUG AND TREATMENT *****ALSO ORDER SUB ACUTE DKA IV FLUIDS REGIMEN & SUB ACUTE ELECTROLYTE REPLACEMENT on separate forms ***** Condition/Status For purpose of this DKA Regimen, DKA is considered clear
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Afrezza Page 1 of 7 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Afrezza (human insulin) Prime Therapeutics will review Prior Authorization requests Prior Authorization
More informationINSULIN THERAPY. Rungnapa Laortanakul, MD Maharat Nakhon Ratchasima hospital
INSULIN THERAPY Rungnapa Laortanakul, MD Maharat Nakhon Ratchasima hospital 3 Sep. 2013 Case Somsak is a 64-year-old man was diagnosed with T2DM, HT, and dyslipidemia 9 years ago. No history of hypoglycemia
More informationComprehensive Diabetes Treatment
Comprehensive Diabetes Treatment Joshua L. Cohen, M.D., F.A.C.P. Professor of Medicine Interim Director, Division of Endocrinology & Metabolism The George Washington University School of Medicine Diabetes
More information